INDERIDE LA 120 Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Inderide La 120, and when can generic versions of Inderide La 120 launch?
Inderide La 120 is a drug marketed by Wyeth Ayerst and is included in one NDA.
The generic ingredient in INDERIDE LA 120 is hydrochlorothiazide; propranolol hydrochloride. There are thirty-two drug master file entries for this compound. Additional details are available on the hydrochlorothiazide; propranolol hydrochloride profile page.
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for INDERIDE LA 120?
- What are the global sales for INDERIDE LA 120?
- What is Average Wholesale Price for INDERIDE LA 120?
Summary for INDERIDE LA 120
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| DailyMed Link: | INDERIDE LA 120 at DailyMed |
US Patents and Regulatory Information for INDERIDE LA 120
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Wyeth Ayerst | INDERIDE LA 120/50 | hydrochlorothiazide; propranolol hydrochloride | CAPSULE, EXTENDED RELEASE;ORAL | 019059-002 | Jul 3, 1985 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
